Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease

Abstract

Objective

The objective of this study was to assess the safety and efficacy of abatacept in patients with SLE refractory to conventional treatment in routine clinical practice.

Methods

This retrospective study included 11 SLE patients treated with abatacept for an active and refractory disease. The primary endpoint was the change in SLE Disease Activity Index (SLEDAI) score at six months. Response was defined as a decrease of SLEDAI ≥4 in a patient continuing abatacept.

Results

Indications of abatacept treatment were articular (n=8), renal (n=1) and cutaneous (n=1) involvement and autoimmune thrombocytopenia (n=1). Abatacept was discontinued before six months in two patients, because of adverse event (n=1) and/or lupus flare (n=2). The median SLEDAI decreased from 6 (2–20) to 4 (0–20) (p=0.031). Decrease of SLEDAI ≥4 was observed in 6/11 patients (55%) and response to treatment according to the physician's judgement in 8/11 (73%) patients. Improvement of articular involvement was observed in 7/8 (87.5%) patients. Four adverse events were observed in three patients, but no severe infection occurred.

Conclusion

This study suggests some efficacy of abatacept in patients with refractory disease in routine clinical practice, particularly in the case of articular manifestations, with an acceptable safety profile. These data support conducting new controlled trials of abatacept in SLE patients.

Keywords

Systemic lupus erythematosus SLE abatacept efficacy safety articular manifestations

Get full access to this article

View all access options for this article.

References

Daikh

Wofsy

. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001; 166: 2913–2916.

Daikh

Finck

Linsley

. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997; 159: 3104–3108.

Furie

Nicholls

Cheng

T-T

. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheum 2014; 66: 379–389.

Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2015; 74: 2006–2015.

Merrill

Burgos-Vargas

Westhovens

. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 3077–3087.

Wofsy

Hillson

Diamond

. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012; 64: 3660–3665.

Ikeda

Sanayama

Makita

. Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol 2013; 2013: Article ID 697525–Article ID 697525.

Rovin

Furie

Latinis

. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215–1226.

Merrill

Buyon

Furie

. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011; 20: 709–716.

10.

Duxbury

Combescure

Chizzolini

. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 2013; 22: 1489–1503.

11.

Terrier

Amoura

Ravaud

. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab Registry. Arthritis Rheum 2010; 62: 2458–2466.

12.

Petri

Orbai

A-M

Alarcón

. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

13.

Wollaston

Farewell

Isenberg

. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol 2004; 31: 2390–2394.

14.

Petri

Kim

Kalunian

. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.

15.

Furie

Petri

Wallace

. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61: 1143–1151.

16.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

17.

Weening

D'Agati

Schwartz

. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521–530.

18.

Conaghan

Durez

Alten

. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 2013; 72: 1287–1294.

19.

The ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheum 2014; 66: 3096–3104.

20.

Wofsy

Hillson

Diamond

. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum 2013; 65: 1586–1591.

21.

Wallace

Kalunian

Petri

. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014; 73: 183–190.

22.

Navarra

Guzmán

Gallacher

. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721–731.

23.

Furie

Petri

Zamani

. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918–3930.